CT-based body composition in diffuse large B cell lymphoma patients: changes after treatment and association with survival.
Humans
Antibodies, Monoclonal, Murine-Derived
/ adverse effects
Positron Emission Tomography Computed Tomography
Disease-Free Survival
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Rituximab
/ therapeutic use
Lymphoma, Large B-Cell, Diffuse
/ diagnostic imaging
Vincristine
/ therapeutic use
Doxorubicin
/ therapeutic use
Treatment Outcome
Body composition
Bone mineral density
CT
Non-hodgkin lymphoma
Journal
La Radiologia medica
ISSN: 1826-6983
Titre abrégé: Radiol Med
Pays: Italy
ID NLM: 0177625
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
01
02
2023
accepted:
05
09
2023
medline:
7
12
2023
pubmed:
27
9
2023
entrez:
26
9
2023
Statut:
ppublish
Résumé
Primary purpose was to assess changes of bone mineral density (BMD) in diffuse large B cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone R-CHOP (like) chemotherapy regimen. Secondary purposes were to assess other body composition features changes and to assess the association of pre-therapy values and their changes over time with survival. Patients selected underwent R-CHOP(like) regimen for DLBCL, and underwent PET-CT before and after treatment. Main clinical data collected included body mass index, date of last follow-up, date of progression, and date of death. From the low-dose CT images, BMD was assessed at the L1 level; the other body composition values, including muscle and fat distribution, were assessed at the L3 level by using a dedicated software. Descriptive statistics were reported as median and interquartile range, or frequencies and percentages. Statistical comparisons of body composition variables between pre- and post-treatment assessments were performed using the Wilcoxon matched pairs signed rank test. Non-normal distribution of variables was tested with the Shapiro-Wilk test. For qualitative variables, the Fisher exact test was used. Log rank test was used to compare survival between different subgroups of the study population defined by specific body composition cutoffs. The significance level was set at p < 0.05. Eighty-two patients were included. The mean follow-up was 37.5 ± 21.4 months. A significant difference was found in mean BMD before and after R-CHOP(like) treatment (p < 0.0001). The same trend was observed for mean skeletal muscle area (SMA) (p = 0.004) and mean skeletal muscle index (SMI) (p = 0.006). No significant association was demonstrated between body composition variables, PFS and OS. R-CHOP(like) treatment in DLBCL patients was associated with significant reduction of BMD, SMA and SMI.
Identifiants
pubmed: 37752299
doi: 10.1007/s11547-023-01723-5
pii: 10.1007/s11547-023-01723-5
pmc: PMC10700208
doi:
Substances chimiques
Antibodies, Monoclonal, Murine-Derived
0
Rituximab
4F4X42SYQ6
Vincristine
5J49Q6B70F
Doxorubicin
80168379AG
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1497-1507Informations de copyright
© 2023. The Author(s).
Références
Front Oncol. 2022 Sep 29;12:974116
pubmed: 36249069
Semin Arthritis Rheum. 2023 Feb;58:152144
pubmed: 36521287
Radiology. 2005 Aug;236(2):671-5
pubmed: 16040924
Radiographics. 2021 Mar-Apr;41(2):524-542
pubmed: 33646902
Leuk Lymphoma. 2007 Aug;48(8):1514-21
pubmed: 17701582
Front Oncol. 2021 Nov 16;11:718815
pubmed: 34868915
J Gerontol A Biol Sci Med Sci. 1995 Jul;50(4):M211-5
pubmed: 7614243
J Natl Cancer Inst. 2016 Jul 05;108(11):
pubmed: 27381623
Ann Oncol. 2013 Mar;24(3):561-76
pubmed: 23175624
J Bone Miner Res. 2011 Sep;26(9):2194-203
pubmed: 21590738
RMD Open. 2022 Jun;8(2):
pubmed: 35732346
Proc Nutr Soc. 2018 May;77(2):135-151
pubmed: 29745361
Cancer Treat Rev. 2015 Nov;41(9):798-808
pubmed: 26410578
Ann Oncol. 2014 Feb;25(2):481-6
pubmed: 24401926
Br J Radiol. 2018 Dec;91(1092):20180451
pubmed: 30179038
Leuk Lymphoma. 2022 Feb;63(2):326-334
pubmed: 34668817
Curr Oncol. 2021 Mar 23;28(2):1325-1337
pubmed: 33806839
Front Oncol. 2022 Mar 15;12:826058
pubmed: 35372021
N Engl J Med. 2002 Jan 24;346(4):235-42
pubmed: 11807147
J Clin Oncol. 2013 Apr 20;31(12):1539-47
pubmed: 23530101
Lancet. 2017 Jul 15;390(10091):298-310
pubmed: 28153383
Quant Imaging Med Surg. 2022 Feb;12(2):1450-1466
pubmed: 35111638
Behav Res Methods. 2007 May;39(2):175-91
pubmed: 17695343
Radiology. 2019 May;291(2):360-367
pubmed: 30912719
Rev Med Chil. 2020 Nov;148(11):1558-1567
pubmed: 33844761
J Natl Compr Canc Netw. 2021 Nov;19(11):1218-1230
pubmed: 34781267
Leuk Lymphoma. 2022 Jul;63(7):1556-1565
pubmed: 35105266
Annu Rev Immunol. 2006;24:33-63
pubmed: 16551243
Leuk Lymphoma. 2017 May;58(5):1105-1113
pubmed: 27736260
PLoS One. 2013 Oct 30;8(10):e78043
pubmed: 24205081